Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | TBK1 | Q9UHD2 | 7/20 | 0.40 |
| ▸ | SYK | P43405 | 1/20 | 0.38 |
| ▸ | AURKA | O14965 | 1/20 | 0.38 |
| ▸ | EGFR | P00533 | 3/20 | 0.37 |
| ▸ | STK17B | O94768 | 1/20 | 0.37 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.37 |
| ▸ | IKBKE | Q14164 | 2/20 | 0.36 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.36 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.36 |
| ▸ | KDR | P35968 | 1/20 | 0.36 |
| ▸ | ERBB2 | P04626 | 3/20 | 0.36 |
| ▸ | SRC | P12931 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18995012 | 0.85 | BCL6 (0.43) | SYKEGFRSTK17BSTK17A | |
| SCHEMBL18995121 | 0.82 | NPC1 (0.47) | NPC1RAB9AMAPTTBK1IKBKE | |
| SCHEMBL19836643 | 0.75 | EGFR (0.41) | TBK1SYKEGFRERBB2 | |
| SCHEMBL18995069 | 0.73 | ULK1 (0.44) | SYKAURKASTK17BSTK17AKDR | |
| SCHEMBL19527748 | 0.73 | TBK1 (0.37) | NPC1RAB9ATBK1SYKEGFR | |
| SCHEMBL19527725 | 0.73 | TNIK (0.39) | MAPTTBK1SYKAURKAEGFR | |
| SCHEMBL6222695 | 0.70 | NPC1 (0.60) | NPC1RAB9AMAPTSYKEGFR | |
| SCHEMBL18995059 | 0.69 | EGFR (0.41) | SYKEGFRSTK17BSTK17AERBB2 | |
| SCHEMBL2447886 | 0.67 | NPC1 (0.74) | NPC1RAB9AMAPTSYKAURKA | |
| SCHEMBL18995005 | 0.67 | BCL6 (0.41) | SYKAURKAEGFRSTK17BSTK17A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10005777-B2 | Protein kinase C inhibitors and uses thereof | RIGEL PHARMACEUTICALS, INC. (US) | 2018-06-26 | — | — | US | disclosed |
| US-20180030050-A1 | Protein Kinase C Inhibitors and Uses Thereof | MIDCAP FINANCIAL TRUST | 2018-02-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10005777-B2 | Protein kinase C inhibitors and uses thereof | PRKCH, PRKCA, PRKCB | NPC1 1483/4885RAB9A 1427/4885MAPT 2530/4885 |
| US-20180030050-A1 | Protein Kinase C Inhibitors and Uses Thereof | PRKCH, PRKCA, PRKCB | NPC1 1483/4885RAB9A 1427/4885MAPT 2530/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.